Transforming Sanofi-Aventis
|
|
ICMR HOME | Case Studies Collection
Case Details:
Case Code : BSTR358
Case Length : 18 Pages
Period : 2008-2009
Pub Date : 2010
Teaching Note :Not Available
Organization : Sanofi-Aventis
Industry : Healthcare / Pharmaceuticals
Countries : France; Global
To download Transforming Sanofi-Aventis case study
(Case Code: BSTR358) click on the button below, and select the case from the list of available cases:
Price:
For delivery in electronic format: Rs. 300;
For delivery through courier (within India): Rs. 300 + Rs. 25 for Shipping & Handling Charges
» Business Strategy Case Studies
» Case Studies Collection
» Business Strategy Short Case Studies
» View Detailed Pricing Info
» How To Order This Case
» Business Case Studies
» Area Specific Case Studies
» Industry Wise Case Studies
» Company Wise Case Studies
Please note:
This case study was compiled from published sources, and is intended to be used as a basis for class discussion. It is not intended to illustrate either effective or ineffective handling of a management situation. Nor is it a primary information source.
|
|
<< Previous
Excerpts Contd...
Diversification
|
According to Viehbacher, in order to serve the world's population, Sanofi-Aventis had to move away from the blockbuster model and strengthen its presence in other healthcare segments such as vaccines, consumer health, generics, and biologics...
Disciplined Acquisitions
Experts felt that patent expiries, unproductive R&D pipelines, fewer drugs approved each year and lower sales from new drugs, were forcing old-line pharmaceutical companies to opt for mega-mergers or bolt-on acquisitions. Mega-mergers were multi-billion dollar deals between two major pharmaceutical companies aimed at creating a company with more drugs and opportunities to cut costs...
|
|
Looking Ahead
For the first half of 2009, the company showed good performance. In particular, Sanofi-Aventis's Q2 revenue and net profit increased significantly over the previous year, and the company raised its 2009 earnings-per-share guidance by three percentage points to 10%...
Exhibits
Exhibit I: Consolidated Income Statement: First Half 2009 (€
million)
Exhibit II: Sanofi-Aventis Five-Year Stock Chart
Exhibit III: Sanofi-Aventis' Position in Various Segments: 2008
Exhibit IV: Top Ten Pharmaceutical Companies by Global Sales
Exhibit V: Sanofi-Aventis' Income Statement
Exhibit VI: Sanofi-Aventis' Balance sheet
Exhibit VII: Sanofi-Aventis' Financial Ratios
Exhibit VIII: Sanofi-Aventis' Top Products: 2008
Exhibit IX: Sanofi-Aventis' R&D Portfolio
Exhibit X: New Drug Development Timeline for the US
Exhibit XI: Global Pharmaceutical Sales by Region: 2008
Exhibit XII: Top Ten Pharmaceutical Companies after Mergers
|
